Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Association of CYP2C192 and 17 genetic variants with hypertension in Pakistani population

Sana Riaz^1,2, Atika Mansoor¹, Saima Siddiqi¹, Muhammad Usman Tareen², Sana Rubab², Ayesha Batool², Anwarullah ², Aneesa Sultan²

¹Institute of Biomedical Genetic Engineering (IBGE), 24 Mauve Area, G-9/1, Islamabad; ²Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan.

For correspondence:- Aneesa Sultan Email: aneesa@qau.edu.pk Tel:+925190643223

Accepted: 13 March 2019 Published: 30 April 2019

Citation: Riaz S, Mansoor A, Siddiqi S, Tareen MU, Rubab S, Batool A, et al. Association of CYP2C19*2 and *17 genetic variants with hypertension in Pakistani population. Trop J Pharm Res 2019; 18(4):851-855 doi: 10.4314/tjpr.v18i4.24

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the association of *2 and *17 single nucleotide polymorphisms (SNPs) of CYP2C19 gene with hypertension in Pakistani population.

Methods: The study was conducted on 527 hypertensive patients and 530 unrelated healthy controls from selected regions of Pakistan. DNA was extracted from leukocytes and all patients and controls were genotyped for two SNPs (rs4244285 and rs12248560) of CYP2C19 gene by allele specific polymerase chain reaction (AS-PCR).

Results: Multi-allelic polymorphism in CYP2C19 identified four distinct phenotypes known as ultra-rapid metabolizer (UM), extensive metabolizer (EM), intermediate metabolizer (IM) and poor metabolizer (PM) in hypertensive patients and controls. For CYP2C19*2 polymorphisms, overall wild type and mutant allele frequency were 75 and 25 % in hypertensive patients, and 64.2 and 35.8 % in controls. For CYP2C19*17 polymorphisms, the overall wild type and mutant allele frequency were 66.6 and 33.4 % in hypertensive patients and 75.6 % and 24.4 % in controls. Significant difference in allele frequencies for CYP2C19*2 and *17 was demonstrated between hypertensive and non-hypertensive subjects.

Conclusion: To the best of our knowledge, this is the first report on CYP2C19 frequencies in hypertensive Pakistani patients. The finds should help clinicians to determine a suitable optimal dosage of some drugs in order to reduce side effects.

Keywords: CYP2C19, Genotyping, Single nucleotide polymorphism, Adverse drug reactions, Pakistani population